iBio, Inc. (NASDAQ:IBIO) Receives Consensus Rating of “Buy” from Brokerages

iBio, Inc. (NASDAQ:IBIO) has received a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and three have given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $5.00.

Several research firms have recently weighed in on IBIO. Chardan Capital reissued a “buy” rating and issued a $5.00 price objective on shares of iBio in a research report on Thursday, April 9th. Raymond James Financial began coverage on iBio in a research report on Monday, June 8th. They issued an “outperform” rating and a $5.00 price objective for the company. JonesTrading began coverage on iBio in a research report on Tuesday, March 3rd. They issued a “buy” rating and a $7.00 price objective for the company. B. Riley Financial began coverage on iBio in a research report on Friday, June 5th. They issued a “buy” rating and a $6.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research report on Friday, March 27th.

iBio Stock Performance

IBIO opened at $1.69 on Friday. iBio has a 1-year low of $0.56 and a 1-year high of $3.82. The stock has a market capitalization of $83.96 million, a price-to-earnings ratio of -2.91 and a beta of 1.26. The business has a 50 day moving average of $1.78 and a 200-day moving average of $2.03.

iBio (NASDAQ:IBIO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Equities analysts predict that iBio will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. PFG Investments LLC bought a new position in iBio in the fourth quarter worth $41,000. XTX Topco Ltd bought a new position in iBio in the fourth quarter worth $71,000. Persistent Asset Partners Ltd bought a new position in iBio in the fourth quarter worth $76,000. Susquehanna International Group LLP bought a new position in iBio in the third quarter worth $37,000. Finally, Cubist Systematic Strategies LLC bought a new position in iBio in the first quarter worth $224,000. 7.90% of the stock is owned by institutional investors.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.